Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159912 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
NCT01159912 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 350 participants.
The verdict
NCT01159912, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
Study Summary
A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.
Interventions
- DRUG Placebo
- DRUG Fluticasone propionate
- DRUG Fluticasone furoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2010-06-30 |
| Est. Completion | 2012-01-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159912
The ClinicalTrials.gov registry entry for NCT01159912 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01159912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159912 about?
NCT01159912 is a clinical study titled "Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents". A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.
What is the current status of trial NCT01159912?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2010-06-30. Estimated completion is 2012-01-16.
What interventions are being tested in trial NCT01159912?
The interventions under investigation include: Placebo (DRUG), Fluticasone propionate (DRUG), Fluticasone furoate (DRUG).
Who is sponsoring clinical trial NCT01159912?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.